Skip to main content

Press Releases

See All
  • 03/23/2021
    Sarepta Therapeutics Announces Fourth Year of Route 79, The Duchenne Scholarship Program
  • 03/18/2021
    Sarepta Therapeutics’ Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Expression and Functional Improvements 2 Years After Administration
  • 03/15/2021
    Sarepta Therapeutics to Present Results from its Gene Therapy and RNA Platforms at the 2021 Annual MDA Clinical and Scientific Conference

Press Contact

Tracy Sorrentino
Senior Director, Public Relations
Sarepta Therapeutics, Inc.
[email protected]
617-274-4052

News Features

View All

  • ami kabadi
    01/13/2021
    How a collaboration in the lab led to a seat at the table in Sarepta’s Gene Editing Innovation Center
  • together we soar
    12/18/2020
    Giving Thanks for Our Employees’ Incredible Dedication: Six Employees Explain Why Sarepta is a Top Place to Work
  • GT-FAQ
    10/14/2020
    Welcome to GT‐FAQ!
  • style="margin: 0 0 2em 2em;"
    09/29/2020
    Expanding Access to Newborn Screening for Those with Rare Diseases
  • Alex headshot full res
    09/14/2020
    Room to Grow – From Sarepta Intern to Making Impact on the Pipeline
  • julianna thumbnail
    06/12/2020
    Patiently Waiting

Utility Menu

  • Investors
  • Newsroom
  • Contact Us

Regional Navigation

  • global sites
    Global Sites
    • brazil
      Brazil
      • Portugues
    • france
      France
      • Français
    • germany
      Germany
      • Deutsch
    • Italian flag
      Italy
      • Italiano
    • japan
      Japan
      • Japanese
    • Switzerland flag
      Switzerland
      • Deutsch
      • English
      • Français
      • Italiano
    • UK flag
      UK
      • English
    • global sites
      United States
      • English
Sarepta Corporate Rebuild

Sarepta Corporate Rebuild

Utility Menu

  • Investors
  • Newsroom
  • Contact Us

Regional Navigation

  • global sites
    Global Sites
    • brazil
      Brazil
      • Portugues
    • france
      France
      • Français
    • germany
      Germany
      • Deutsch
    • Italian flag
      Italy
      • Italiano
    • japan
      Japan
      • Japanese
    • Switzerland flag
      Switzerland
      • Deutsch
      • English
      • Français
      • Italiano
    • UK flag
      UK
      • English
    • global sites
      United States
      • English
Home

Main navigation

  • Our Disease Areas
    • Duchenne Muscular Dystrophy
    • Limb-girdle Muscular Dystrophy
    • Mucopolysaccharidosis Type IIIA
    • Charcot-Marie-Tooth Disease
  • Our Science
    • Gene Therapy Engine
    • RNA Platform
    • Gene Editing
    • Manufacturing
    • Strategic Partnerships
  • Our Products & Pipeline
    • Products
    • Pipeline
    • Clinical Trials
    • Treatment Access
  • About Us
    • Leadership
    • Patient Advocacy
    • Corporate Responsibility
    • Grants & Giving
    • Global Locations
    • Contact Us
  • Join Us
    • Career Opportunities

Social Links

  • Twitter
  • LinkedIn
  • Instagram
  • Facebook

Newsroom

Press Releases
News Features
Media Library
Press Contact

Press Releases

See All
  • 03/23/2021
    Sarepta Therapeutics Announces Fourth Year of Route 79, The Duchenne Scholarship Program
  • 03/18/2021
    Sarepta Therapeutics’ Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Expression and Functional Improvements 2 Years After Administration
  • 03/15/2021
    Sarepta Therapeutics to Present Results from its Gene Therapy and RNA Platforms at the 2021 Annual MDA Clinical and Scientific Conference

News Features

View All

  • ami kabadi
    01/13/2021
    How a collaboration in the lab led to a seat at the table in Sarepta’s Gene Editing Innovation Center
  • together we soar
    12/18/2020
    Giving Thanks for Our Employees’ Incredible Dedication: Six Employees Explain Why Sarepta is a Top Place to Work
  • GT-FAQ
    10/14/2020
    Welcome to GT‐FAQ!
  • style="margin: 0 0 2em 2em;"
    09/29/2020
    Expanding Access to Newborn Screening for Those with Rare Diseases
  • Alex headshot full res
    09/14/2020
    Room to Grow – From Sarepta Intern to Making Impact on the Pipeline
  • julianna thumbnail
    06/12/2020
    Patiently Waiting

Media Library

View All Media Library

Sarepta Corporate Logo Horizontal Full Color

Sarepta Corporate Logo

Download

Sarepta Building Exterior thumbnail

Sarepta Building Exterior

Download

LGMD Fact sheet thumbnail

LGMD Fact Sheet

Download

NSAA Fact Sheet Thumbnail

NSAA Fact Sheet

Download

Press Contact

Tracy Sorrentino
Senior Director, Public Relations
Sarepta Therapeutics, Inc.
[email protected]
617-274-4052

Follow Us On Social

  • Twitter
  • LinkedIn
  • Instagram
  • Facebook

Main navigation

  • Our Disease Areas
    • Duchenne Muscular Dystrophy
    • Limb-girdle Muscular Dystrophy
    • Mucopolysaccharidosis Type IIIA
    • Charcot-Marie-Tooth Disease
  • Our Science
    • Gene Therapy Engine
    • RNA Platform
    • Gene Editing
    • Manufacturing
    • Strategic Partnerships
  • Our Products & Pipeline
    • Products
    • Pipeline
    • Clinical Trials
    • Treatment Access
  • About Us
    • Leadership
    • Patient Advocacy
    • Corporate Responsibility
    • Grants & Giving
    • Global Locations
    • Contact Us
  • Join Us
    • Career Opportunities

©2021 Sarepta Therapeutics All rights reserved.

Footer Utility Nav

  • Privacy Policy
  • Terms of Use
  • EU-U.S. and Swiss-U.S. Privacy Shield Policy